Arnold & Porter Represents Aduro Biotech in Major Life Sciences Drug Collaboration with Novartis

April 7, 2015

NEW YORK, April 7, 2015 -- Arnold & Porter recently represented Aduro Biotech, Inc. in the negotiation of a major collaboration with Novartis for the worldwide research, development and commercialization of novel immuno-oncology products derived from Aduro's cyclic dinucleotide (CDN) approach to target the STING (Stimulator of Interferon Genes) receptor, that, when activated, initiates innate and adaptive tumor-specific immune responses. The transaction is the fourth such collaboration and licensing transaction handled by the firm within the last five months -- two of those deals being for Aduro.

Under the terms of the latest agreement, Novartis has paid $200 million to Aduro and, if development milestones are met, Aduro is eligible to receive up to an additional aggregate amount of $500 million. For a more complete description of the key public terms of the transaction, please see Aduro's press release. 

The multi-office Arnold & Porter team handling the Aduro-Novartis collaboration was led by Blaine Templeman and included Scott Lent, Cynthia Mann, Rebecca Crawford, and Naomi Hartman, all resident in firm's New York office; Daniel Kracov, William Bosch and Wasim Quadir in Washington, DC; and Anna Buscall, Richard Dickinson and Lincoln Tsang of the firm's London office. 


Email Disclaimer